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Background: Decompensated cirrhosis is a serious clinical complication of chronic hepatitis B 
(CHB) that places a large economic burden on the US health care system. Although entecavir 
has been shown to improve health outcomes in a cost-effective manner in mixed populations of 
CHB patients, the cost-effectiveness of entecavir has not been evaluated in CHB patients with 
decompensated cirrhosis.
Methods: This study assessed the cost-effectiveness of entecavir versus adefovir, from a US 
payer perspective, in CHB patients with decompensated cirrhosis, using a health-state transition 
Markov model with four health states: hepatocellular carcinoma (HCC), HCC-free survival, post-
liver transplant, and death. The model considered a hypothetical patient population similar to that 
included in a randomized controlled trial in the target population (ETV-048): predominantly male 
(74%), Asian (54%), mean age 52 years, hepatic decompensation (Child–Pugh score $ seven), 
hepatitis B e antigen-positive or -negative, treatment-naïve or lamivudine-experienced, and no 
liver transplant history. Clinical inputs were based on cumulative safety results for ETV-048 
and published literature. Costs were obtained from published literature. Costs and outcomes 
were discounted at 3% per annum.
Results: For 1000 patients over a 3-year time horizon, predicted overall survival and HCC-free 
survival were longer with entecavir than with adefovir (2.35 versus 2.30 years and 2.11 versus 
2.03 years, respectively). Predicted total health care costs were $889 lower with entecavir than 
with adefovir ($91,878 versus $92,768). For incremental cost/life-year gained and incremen-
tal cost/HCC-free-year gained, entecavir was less costly and more effective than adefovir. 
S  ensitivity analyses found the results to be robust to plausible variations in health-state costs 
and discount rate.
Conclusion: This analysis suggests that entecavir improves survival outcomes in a cost-saving 
manner compared with adefovir in CHB patients with hepatic decompensation.
Keywords: hepatocellular carcinoma, antiviral, survival, health economics, incremental net 
benefit
Introduction
The availability of hepatitis B virus (HBV) vaccines has reduced the incidence of acute 
HBV infection in the US; however, the prevalence of chronic hepatitis B (CHB) remains 
high because of immigration from highly endemic countries.1,2 CHB affects up to 
1.4 million individuals in the US and results in approximately 3000 deaths each year due 
to liver disease.1,2 The heterogeneous nature and slow progression of CHB means that 
it is often diagnosed later in life and at later stages of the disease. CHB often has seri-
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ous clinical sequelae, including liver failure, hepatocellular 
carcinoma (HCC), and death, and places a large economic 
burden on the US health care system.3,4
Morbidity and mortality in CHB are linked to persistent 
viral replication resulting in liver injury and the develop-
ment of fibrosis and eventually cirrhosis. Decompensated 
cirrhosis occurs in the later stages of CHB. Patients with 
decompensated cirrhosis have an average 5-year survival 
rate of 14%–35% compared with 80%–86% in patients with 
compensated cirrhosis.5 Survival can be improved and the 
need for liver transplantation can be delayed or prevented by 
antiviral treatment that suppresses HBV viral load and sta-
bilizes or improves disease status.6–8 For patients with HBV 
and decompensated cirrhosis, the most recent US treatment 
guidelines from the American Association for the Study of 
Liver Diseases, published in 2009, recommend prompt initia-
tion of treatment with an oral nucleos(t)ide analog regimen, 
which can produce rapid viral suppression with a low risk of 
resistance.4 Based on evidence from clinical study ETV-048,9 
entecavir was approved by the US Food and Drug Administra-
tion in late 2010 for the treatment of patients with decompen-
sated cirrhosis.10 Adefovir had resulted in improved clinical 
outcomes in a study of pre- and post-transplantation patients, 
including patients with decompensated liver disease,6,8 and 
was accepted by the US Food and Drug Administration as a 
suitable comparator to entecavir in patients with decompen-
sated disease. The ETV-048 study is a prospective, random-
ized, clinical study comparing adefovir and entecavir in 191 
CHB patients with hepatic decompensation (mean baseline 
Child–Turcotte–Pugh score: 8.59).9 Over 48 weeks of treat-
ment, entecavir demonstrated superior antiviral and biochemi-
cal activity compared with adefovir. Over a mean therapy 
time of 109 weeks for entecavir and 97 weeks for adefovir, 
cumulative numbers of patients developing HCC or dying 
were lower in the entecavir arm compared with the adefovir 
arm (12% versus 20% and 23% versus 33%, respectively). 
Two-thirds of patients in both groups demonstrated improve-
ment or stabilization of Child–Turcotte–Pugh status.
With the increasing availability of new antiviral agents 
for the treatment of HBV infection, cost-effectiveness analy-
sis serves as an aid in determining the optimal management 
strategies for CHB patients. Entecavir has been shown to 
improve health outcomes in a cost-effective manner com-
pared with other oral antivirals and pegylated interferon in 
a population of patients with hepatitis B e antigen-positive 
CHB.11 While some previous studies have examined dec-
ompensated cirrhosis as part of broader cost-effectiveness 
analyses of CHB management, there is a lack of economic 
health studies that evaluate the cost-effectiveness of antivi-
ral treatments solely in CHB patients with decompensated 
liver disease in the US.12–17 The objective of this analysis 
was to evaluate the cost-effectiveness of entecavir versus 
adefovir from a US third-party payer perspective in treating 
CHB among patients with decompensated cirrhosis using 
published evidence and safety data extrapolated from a 
prospective clinical study in the target population (study 
ETV-048).
Methods
Model description
The model was constructed in Microsoft Excel 2007 as 
a four-state deterministic Markov model, defined by the 
clinical events of interest (Figure 1). A Markov model 
(as opposed to a decision tree framework) was chosen to 
allow for the incorporation of time spent in the various 
health states associated with HBV-related decompensated 
cirrhosis. The four health states simulated in the model were 
HCC, HCC-free decompensated cirrhosis, survival post-
liver transplant, and death. Patients entered the model with 
decompensated cirrhosis in the HCC-free decompensated 
cirrhosis state and exited the model at death or at the end 
of the model time horizon. The model was programed to 
consider a hypothetical population of 1000 patients similar 
to those included in the ETV-048 study, that is, adults ($16 
Post-liver
transplant
HCC
Death
HCC-free
decompensated
cirrhosis
Figure 1 Diagram of the four-state Markov model.
Notes:  All  patients  enter  the  model  in  hepatocellular  carcinoma  (HCC)-free 
decompensated cirrhosis state. Patients with HCC-free decompensated cirrhosis 
are  at  risk  of  developing  HCC.  HCC  patients  and  HCC-free  decompensated 
cirrhosis patients are both eligible for liver transplantation with equal probability. 
Post-liver-transplant patients have a lower death rate than HCC and HCC-free 
decompensated cirrhosis patients. Death is the only absorbing state.
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years) with hepatitis B e antigen-positive or -negative CHB 
and hepatic decompensation (Child–Turcotte–Pugh score $ 
seven).9 Patients were treatment-naïve or previously treated 
with lamivudine (  lamivudine resistance-associated muta-
tions present or absent), and had not received any previous 
liver transplant.
The model predicted and compared entecavir- and 
adefovir-specific health outcomes and associated costs over 
a 3-year time horizon using repeated 4-week cycles. A 3-year 
time horizon was chosen since this is the duration typically 
of interest to US third-party payers, based on the average 
length of enrollment in commercial plans. The cycle length 
was selected based on the reported data from clinical study 
ETV-048, which provided HCC-free survival estimates at 
4-week intervals. A half-cycle correction was applied to 
cost and survival outputs from the  i.e. cycle-specific calcu-
lations of the model. The standard discount rate of 3% (as 
recommended by the US Public Health Service Panel on 
Cost-effectiveness in Health and Medicine) was applied to 
costs and health outcomes every 4 weeks after the first year 
of treatment, subject to half-cycle correction.18
Model parameters and inputs
A summary of the parameters and inputs used within the 
model, and the sources they are based on, is provided in 
Table 1.
Modeling treatment-specific health-state  
transition probabilities
Following each cycle, the transition probabilities for entering 
the HCC disease state, remaining in the HCC-free decom-
pensated cirrhosis state, and moving from the HCC-free 
decompensated cirrhosis state to the death state were based 
on parametric regression analysis of as-treated, cumulative 
HCC-free survival, and overall survival data from clinical 
study ETV-048 (Figure 2A and B). Overall survival for 
adefovir and HCC-free survival for both arms were derived 
from summary Kaplan–Meier data with a 240-week follow 
up. The Kaplan–Meier overall survival data for the entecavir 
group showed flattening after week 96, so the data were trun-
cated at this point to allow for a good fit. Parametric survival 
techniques were used to identify the best-fitting   distribution. 
Exponential, Weibull, and log-logistic distributions were 
considered and the method yielding the closest fit was chosen. 
To ensure that the best-fitting distribution did not deviate 
significantly from the observed data, the observed versus 
predicted distribution by treatment group for each outcome 
were examined.
Weibull curves were used for adefovir overall survival and 
adefovir HCC-free survival. Sequential Weibull curves were 
used for entecavir overall survival and entecavir HCC-free 
survival data. All other health state transition probabilities in 
the model were estimated as being identical for each of the 
treatment regimens. As such, overall survival and HCC-free 
survival represent the primary drivers of the model.
Other health-state transition probabilities
Treatment-independent health-state transition   probabilities 
were based on published literature. The probability of receiv-
ing a liver transplant was considered to be the same for 
patients with and without HCC and was based on Organ Pro-
curement and Transplantation Network data as of March 4, 
2011, which described the 2-year probability of receiving a 
liver transplant as 51.7% for patients with model for end-
stage liver disease scores between 11 and 18.19 Patients in 
the HCC-free decompensated cirrhosis state were assumed 
to only be eligible for liver transplant in the first year of dis-
Table 1 Model parameters and inputs used in the reference case
Parameter/input Value Sources
Time horizon (years) 3
Discount rate (costs only;  
applicable after the first  
year of treatment)
3.00% 19
Rate of mortality for patients  
without HCC
Regression model based  
on ETV-048 data
10
HCC-free survival Regression model based  
on ETV-048 data
10
Treatment duration Regression model based  
on ETV-048 data
10
Probability of liver transplant  
per 28 days (HCC-free or  
HCC states)
0.028 20
Annual probability of survival,  
post-liver-transplant
0.936 21
Probability of mortality from  
HCC per 28 days
0.056 22
Drug cost per dose (AWP) Entecavir 1.0 mg: $28.37
Adefovir 10 mg: $32.52
23
Drug cost per cycle  
(28 days) following  
AWP reimbursement
Entecavir (1.0 mg): $666.45
Adefovir (10 mg): $764.06
23–25
AWP reimbursement  
(% of drug cost)
16.10% 24, 25
Annual cost of decompensated  
cirrhosis without HCC
$17,051 3
Annual cost of HCC $33,875 5
Cost per liver transplant $128,789 3
Annual cost for post-liver- 
transplant health care
$18,689 3
Cost per death $10,683 26, 27
Note: Costs were inflated to 2010 US$ where necessary.
Abbreviations: AWP, average wholesale price; HCC, hepatocellular carcinoma.
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ease. Patients in the HCC state were assumed to be eligible 
for liver transplant in the first 3 months of disease only. This 
assumption is consistent with previous models of HCC 
liver transplantation28 and was based on the Milan eligibil-
ity criteria, which state that patients with HCC should only 
be considered for liver transplantation at an early stage of 
tumor development.29 The probability of post-liver-transplant 
survival was based on a Milliman Research Report from 
2008, which reported a 5-year post-transplant survival rate of 
86%.20 The probability of mortality from HCC was based on 
a retrospective analysis by Altekruse et al, who searched the 
Surveillance, Epidemiology, and End Results database and 
reported a 1-year survival rate of 47% among HCC patients.21 
Transition probabilities were converted into probabilities per 
28-day cycle for use in the model.
Treatment duration and drug costs
Cumulative drug costs are estimated by enumerating the 
number of patients remaining on therapy following each 
cycle based on regression analyses of as-treated,   cumulative 
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Figure 2 Regression analysis on cumulative ETV-048 data for hepatocellular carcinoma (HCC)-free survival (A), overall survival (B), and treatment duration (C) data for 
entecavir and adefovir.
Note: Solid lines show the observed outcome and dashed lines the predicted outcome.
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entecavir and adefovir treatment duration data over 240 
weeks in clinical study ETV-048 (Figure 2C). In both cases, 
Weibull curves were used to fit the data. In keeping with 
the third-party payer perspective of the analysis, the cost of 
entecavir and adefovir in the reference case were based on 
the US average wholesale price in October 2010 (entecavir, 
$28.37 per dose; adefovir, $32.52 per dose).22 An entecavir 
dose of 1.0 mg per day was used because the patient popula-
tion included patients who had been previously treated with 
lamivudine. Drug costs were scaled to 4 weeks to match the 
modeled cycle length and reduced by 16.1% to reflect the 
average community pharmacy reimbursement for brand name 
drugs as described in a 2008 survey of 223 employees.23,24
Disease management costs
Disease management costs were derived from published 
sources and inflated to 2010 US$, where necessary, using 
the medical care component of the US consumer price 
index. The cost per liver transplantation, the annual cost 
of patient management following liver transplantation, and 
the annual cost of managing patients with decompensated 
cirrhosis were based on an analysis of health care claims 
data conducted by Lee et al in which cost estimates were 
based on reimbursed amounts for each claim.3 The annual 
cost of HCC was based on a previous investigation by Lang 
et al using the Surveillance, Epidemiology, and End Results 
Medicare database.25 The per-event cost of death was calcu-
lated from average health care utilization statistics for end-
of-life patients as described in the Dartmouth Atlas Project, 
and 2010 unit costs listed by the Centers for Medicare and 
Medicaid Services.26,27
Model outputs
The primary health outcomes predicted by the model were 
mean overall survival (years), mean HCC-free survival 
(years), and liver transplants (number per population). The 
primary economic outcomes of the model were treatment-
specific total medical costs, including antiviral costs, cost of 
decompensated cirrhosis, cost of HCC, cost of transplant, 
and cost of death. Incremental cost-effectiveness ratios for 
HCC-free survival and overall survival were calculated as 
the ratio between the difference in medical care costs and the 
difference in the rates of respective health outcomes between 
entecavir and adefovir.
The incremental net benefit was also calculated. That is, 
the total cash benefit if the health outcome is converted to a 
dollar value by multiplying the difference in health outcome 
by the willingness-to-pay threshold minus the difference in 
total medical costs. For this purpose, a willingness-to-pay 
threshold of US$50,000 was used. A positive net benefit 
means the treatment of interest is favorable against the 
comparator and vice versa.
Sensitivity analysis
A univariate sensitivity analysis was undertaken to test the 
robustness of the model. The time horizon for follow up was 
varied between 1 and 5 years. The discount rate was varied 
from 0% to 6%. The cost of entecavir and adefovir were 
varied to reflect the wholesale acquisition cost ($709.23 
and $813.11, respectively) without adjustment for pharmacy 
reimbursement.22 Average wholesale price reimbursement 
was varied to reflect the lowest and highest discount rates 
reported in the survey cited for the reference case.24 The 
annual cost of decompensated cirrhosis and the cost of liver 
transplant were reduced by 25% or increased to use the cost 
estimate based on hospital charges rather than reimbursed 
costs.3 The annual cost of HCC was varied to reflect the 
lowest and highest costs reported by Lang et al for different 
stages of HCC (localized versus distant). The annual cost of 
post-liver-transplant health care was varied using alternative 
data sources.28,30 Minimum and maximum estimates of event 
cost for death were derived using the standard error reported 
for the daily hospital stay cost used to derive the estimate.26,27 
The annual probability of post-liver-transplant survival was 
varied to reflect the 1-year survival rate (86%) reported in 
the 2008 Milliman Research Report.20 Overall survival, 
HCC-free survival, and treatment duration for the entecavir 
arm were individually set to match those derived from the 
adefovir clinical study data. The addition of tenofovir as a 
salvage therapy in patients who discontinued treatment with 
entecavir or adefovir was also considered. Furthermore, the 
addition of lamivudine (100 mg daily) to the adefovir arm 
was considered to reflect the guideline recommendation not 
to use adefovir as a monotherapy in patients with decom-
pensated cirrhosis.4
Results
Health outcomes, costs, and cost 
effectiveness
Over the 3-year time horizon, entecavir was predicted to 
provide improvements over adefovir in mean overall survival 
(2.35 versus 2.30 years, respectively) and HCC-free survival 
(2.11 versus 2.03 years, respectively; Table 2). Entecavir 
was also expected to provide a marginally greater impact 
on the number of liver transplants over the 3-year period, 
with six fewer transplants per 1000 population predicted 
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under the entecavir regimen than under the adefovir regimen 
(Table 2). These expected improvements in HCC-free survival 
impacted the 3-year projected costs of patient management 
under the two treatment regimens (Table 2). While adefovir 
was predicted to offer mean savings of $1496 per patient in 
the cost of HCC-free decompensated cirrhosis management 
(due to the shorter time patients were expected to spend in 
this state), this saving was exceeded by greater costs in HCC 
patient management, liver transplantation, death, and the 
drug itself, relative to entecavir; for example, entecavir was 
predicted to provide an average saving of $1100 per patient 
in HCC costs compared with adefovir. As a result, over the 
3-year time horizon, total medical costs were projected to be 
lower with entecavir ($91,878) than with adefovir ($92,768), 
providing a net mean saving of $889 (Table 2). Mean antiviral 
costs were $207 lower for entecavir than for adefovir and 
mean total disease state costs were $682 lower for entecavir 
than for adefovir.
The improvements in health outcomes and over-
all cost savings mean that entecavir was the dominant 
  intervention (ie, was more efficacious and less costly) in 
terms of cost per life-year gained and cost per HCC-free 
life-year gained. Assuming a willingness-to-pay threshold 
in the US of $50,000 per year, these improvements corre-
spond to an incremental net benefit of $3656 per patient in 
terms of   overall survival and $5280 per patient in HCC-free 
survival with entecavir versus adefovir over the 3-year time 
horizon.
Sensitivity analysis
A series of univariate sensitivity analyses found the model 
to be robust to plausible variations in health-state costs, drug 
costs, and the discount rate, with only minor changes in net 
benefit observed at the upper and lower bounds of these 
analyses (Table 3). The model was most sensitive to changes 
in HCC-free survival, the time horizon of the model, and the 
inclusion of lamivudine as an add-on therapy to adefovir 
(Table 3). Using the duration of HCC-free survival predicted 
from the ETV-048 adefovir arm for both arms in the model 
negated the net benefit of entecavir over adefovir for HCC-
free survival and reduced the net benefit of entecavir for 
overall survival. Further threshold analyses were conducted 
for this variable to help gain a quantitative understanding of 
the sensitivity. Specifically, HCC-free survival of entecavir 
at the end of 5 years was varied in a stepwise fashion until 
the net benefit over 3 years of either overall or HCC-free life 
-years reached zero. When the HCC-free survival at 5 years 
is decreased by more than 6.2%, the net benefit of HCC-
free life-years will be less than zero (ie, not cost-effective 
at a threshold of $50,000 per year). By the same token, the 
reduction in HCC-free survival needed for overall life-years 
to reach zero was 15.4%.
The net benefit of entecavir increased substantially when 
the time horizon was extended to 5 years and decreased 
when the time horizon was reduced to 1 year; however, 
entecavir remained the most cost-effective treatment across 
all time horizons in the selected range. Lastly, as expected, 
the inclusion of lamivudine as an add-on therapy to adefovir 
substantially increased the net benefit of entecavir.
Discussion
Complications of decompensated cirrhosis are key drivers 
of the costs associated with CHB-related health care.3,4,17 If 
disease progression is allowed to continue in patients with 
decompensated cirrhosis, then liver transplant, at an aver-
age annual cost of more than $100,000, becomes the only   
Table 2 Survival outcomes, health care costs, and incremental 
cost-effectiveness  ratios  for  entecavir  versus  adefovir  in  the 
treatment of decompensated chronic hepatitis B over a 3-year 
time horizon
ETV ADV Difference  
(ETV less ADV)
Health outcomes
Mean overall survival  
(years)
2.35 2.30 0.06
Mean HCC-free survival  
(years)
2.11 2.03 0.09
Number of liver transplants  
(per 1000 population)
281 287 -6.59
Cost outcomes
Mean antiviral costs $13,628 $13,835 -$207
Mean disease state costs
    Decompensated cirrhosis  
without HCC
$25,471 $23,975 $1496
  HCCs $8135 $9235 -$1100
  Liver transplant $41,586 $42,364 -$778
  Death $3058 $3358 -$300
Total disease state costs $78,250 $78,932 -$682
Total average medical costs $91,878 $92,768 -$889
Incremental cost-effectiveness ratios and net benefit  
(ETV versus ADV)
Cost per life-year gained ETV dominant
(less costly and increased life-years)
Cost per HCC-free  
life-year gained
ETV dominant
(less costly and increased HCC-free  
life-years)
Net benefit (life-years) $3656
Net benefit (HCC-free  
life-years)
$5280
Note: Costs were inflated to 2010 US$ where necessary.
Abbreviations: ADV, adefovir; ETV, entecavir; HCC, hepatocellular carcinoma.
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effective therapeutic option.3 The results of this analysis 
suggest that entecavir improves survival outcomes in a cost-
saving manner compared with adefovir in CHB patients with 
hepatic decompensation. For 1000 patients over a 3-year 
time horizon, predicted overall and HCC-free survival were 
longer with entecavir than with adefovir and predicted 
total health care costs were lower with entecavir than with 
  adefovir. Thus, entecavir was the dominant intervention for 
both incremental cost per life-year gained and incremental 
cost per HCC-free life-year gained.
This is the first study to focus on the cost effectiveness of 
antiviral treatments solely in CHB patients with decompen-
sated liver disease. The validity of the model is strengthened 
by the use of extrapolated data from a prospective clinical 
study comparing the two interventions in the target population 
of patients with HBV-related decompensated liver   disease. 
Sensitivity analyses further demonstrated the robustness of 
the model. Varying disease state costs to reflect the ranges 
reported in the literature had little impact on the net benefit of 
entecavir over the 3-year time horizon. However, altering the 
time horizon did have a profound impact on the output of the 
model, suggesting that the added benefit of entecavir versus 
adefovir is not fully realized until more than 1 year after the 
treatment decision. Nevertheless, entecavir did remain the 
most cost-effective treatment over a 1-year time horizon and 
the net benefit of entecavir increased substantially when the 
reference case time horizon was extended to 5 years.
The results of this study highlight the importance of disease 
stabilization in CHB patients with hepatic   decompensation. 
The model predicted that treatment with entecavir would 
result in increased overall survival, increased HCC-free 
survival, and fewer liver transplants compared with adefovir 
treatment. As mortality from HCC, post-liver-transplant mor-
tality, and the probability of liver transplant were modeled 
as equal for both treatment regimens, these improved health 
outcomes can be attributed to entecavir better maintaining 
patients in the HCC-free decompensated cirrhosis state than 
adefovir. Such disease stabilization is of particular impor-
tance for patients who are not liver transplant candidates, as 
prevention of further disease progression may significantly 
defer or prevent complete liver failure, where no further 
treatment options exist. In our model, reduced progression to 
disease states with high health care costs resulted in reduced 
total costs associated with entecavir treatment compared 
with adefovir treatment over the 3-year time horizon. Most 
notably, entecavir was predicted to provide an average saving 
of $1100 per patient in HCC costs compared with adefovir, 
highlighting the major financial benefit of disease stabiliza-
tion in the treatment of decompensated cirrhosis.
There are a number of limitations to this study. Firstly, 
using adefovir as a comparator, although appropriate at the 
time of the ETV-048 study, does not necessarily reflect the 
current treatment practice in the US since tenofovir is now 
also approved for the treatment of CHB patients with dec-
ompensated cirrhosis. Results for entecavir and tenofovir 
might be expected to be comparable, since studies have 
shown that the mean total health care costs associated with 
each agent when used as a monotherapy are comparable31 and 
Table 3 Sensitivity analysis for the estimated net benefit of entecavir versus adefovir in terms of life-years gained and HCC-free life-years 
gained
Parameter/input Value in  
reference  
case
Value in sensitivity 
analysis
Net benefit of ETV versus  
ADV (life years)
Net benefit of ETV versus  
ADV (HCC-free life years)
Lower 
bound
Upper  
bound
Ref case Lower 
bound
Upper 
bound
Ref case Lower 
bound
Upper 
bound
Time horizon (years) 3 1 5 $3656 $709 $9985 $5280 $133 $21,566
Discount rate (%) 3.00 0.00 6.00 $3864 $3467 $5677 $4922
Type of drug cost AWP WACa – $3655 – $5279 –
AWP reimbursement  
(% of drug cost)
-16.10% -12.08% -20.13% $3666 $3646 $5290 $5270
Decompensated cirrhosis  
(annual cost)
$17,051 $12,788 $21,314 $4030 $3282 $5654 $4906
HCC (annual cost) $33,875 $25,406 $42,343 $3381 $3931 $5005 $5555
Liver transplant (event cost) $128,789 $96,592 $160,987 $3463 $3849 $5087 $5473
Post-liver transplant  
(annual cost)
$18,689 $14,017 $23,362 $3655 $3657 $5279 $5281
Death (event cost) $10,683 $8012 $13,354 $3581 $3731 $5205 $5355
Notes: Costs were inflated to 2010 US$ where necessary. aWAC costs for ETV and ADV were considered without adjustment for pharmacy reimbursement.
Abbreviations: ADV, adefovir; AWP, average wholesale price; ETV, entecavir; HCC, hepatocellular carcinoma; WAC, wholesale acquisition cost.
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that the efficacy of these agents in this patient population is 
similar.32 In addition, guidelines issued before the approval 
of tenofovir recommended that adefovir be used in combina-
tion with lamivudine, not as a monotherapy, in patients with 
decompensated cirrhosis.4 The inclusion of costs for add-on 
lamivudine in the adefovir arm goes some way to address 
this limitation; however, the potential clinical benefits that 
might be derived from this addition are not considered. 
Secondly, the emergence of a resistant virus was not specifi-
cally included in the model. The patient population included 
patients with previous lamivudine treatment, in whom the 
risk of emergence of entecavir resistance is greater than in 
treatment-naïve patients.10 In the ETV-048 study, entecavir-
resistant virus variants were detected in three patients, all 
of whom carried lamivudine-resistant variants at baseline, 
and adefovir-resistant virus variants were detected in six 
patients, two of whom carried lamivudine-resistant variants 
at   baseline.9 The development of drug resistance can lead 
to hepatic flares or even death, as well as a loss of efficacy, 
requiring discontinuation of the treatment in   question. How-
ever, since the treatment duration and survival probabilities 
included in the model were derived from clinical data from 
the ETV-048 study, any deaths or treatment discontinuations 
resulting from the emergence of a resistant virus would 
already have been taken into consideration. Thirdly, switching 
to an alternative antiviral therapy following treatment failure 
was not explicitly considered in the model. According to treat-
ment guidelines, patients who failed treatment on adefovir 
could theoretically have added entecavir, telbivudine, or 
lamivudine (if they had no previous lamivudine exposure), 
or switched to tenofovir plus lamivudine, emtricitabine, or 
entecavir; patients failing on entecavir could have switched 
to tenofovir.4,5 A switch to tenofovir in patients discontinu-
ing treatment in either arm was included in the sensitivity 
analysis and had little impact on the resulting net benefit of 
entecavir over adefovir, although it should be noted that any 
potential clinical benefit resulting from this switch was not 
considered. Lastly, it should be noted that this analysis applies 
to a specific patient population (those with HBV-associated 
decompensated cirrhosis) and to a specific health care setting 
(with a US third-party payer perspective), thus the results 
may not be applicable to other patients with CHB or to other 
health care settings.
Treatment guidelines recommend treating HBV infection 
before the development of liver cirrhosis based on viral load 
and serum alanine aminotransferase levels.4,5 This approach 
can significantly delay, or even reverse, the progression of dis-
ease and is clearly more cost effective than waiting to   initiate 
treatment only at the onset of serious illness.11,33 However, 
early treatment is often not possible as it is estimated that 
65% of the HBV-infected population in the US are unaware 
of their infection, meaning that initial diagnosis frequently 
occurs at a late stage of disease progression, when symptoms 
of decompensated cirrhosis are apparent.2 Despite the pref-
erential outcomes of early treatment, it is still beneficial to 
treat HBV with decompensated cirrhosis, as demonstrated in 
the ETV-048 study. The results of this analysis suggest that 
for HBV-infected patients who have progressed to decom-
pensated cirrhosis, entecavir improves survival outcomes in 
a cost-saving manner compared with adefovir.
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